Sjögren's Syndrome is a condition where the immune system attacks the body's moisture-producing glands, causing dryness in the mouth and eyes. This study is testing the safety and effectiveness of the drug Deucravacitinib in adults with active Sjögren's Syndrome. Participants must have had the disease for at least 16 weeks and less than 10 years. They need a certain level of salivary flow and must test positive for specific antibodies.
People with other autoimmune diseases or active fibromyalgia are not eligible. Also, those who have previously taken drugs similar to Deucravacitinib cannot join. The study will involve different doses of the drug to see which works best.
- The study requires adults who have moderate to severe symptoms.
- Participants must not have other autoimmune diseases.
- Previous use of similar drugs disqualifies participation.
How understandable was the trial content above?
Hard to understand
Easy to understand